stockrow
Friday 6 November 2026
Export AVR’s income statement to Excel — free account
Anteris Technologies Global Corp.
AVR Healthcare Medical Devices
Anteris Technologies Global Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 29.2% from fiscal 2024.
- Revenue
- +63.3%
- EPS
- +48.3%
- Free cash flow
- −6.84%
- Total debt
- +8.15%
Quarter to June 2026, against a year earlier
5.71
0.13
+2.33%
Follow AVR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 3 | 3 | 2 | 2 | (16.4%) | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | 32.07 | 46.84 | 70.26 | 74.98 | +38.2 pt | ||||||
| EBT | — | — | — | — | — | — | — | (47) | (76) | (94) | (102) | +41.9% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | (1,709.84) | (2,810.47) | (4,925.51) | (4,568.02) | (3,215.7) pt | ||||||
| Net income | — | — | — | — | — | — | — | (47) | (76) | (94) | (103) | +41.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.18 | 0.13 | 0.05 | 0.02 | (45.6%) | |||||
| Earnings | — | — | — | — | — | — | — | (2.95) | (3.68) | (2.55) | (1.95) | (7.0%) | ||||||
| Cash flow | — | — | — | — | — | — | — | (2.22) | (3.02) | (2.11) | (0.89) | (2.5%) | ||||||
| Capex | — | — | — | — | — | — | — | (0.15) | (0.11) | (0.05) | (0.02) | (41.0%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (2.37) | (3.14) | (2.16) | (0.91) | (4.5%) | ||||||
| Book value | — | — | — | — | — | — | — | 1.21 | 3.10 | (0.01) | 2.59 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 16 | 20 | 37 | 63 | +53.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 41.81 | 96.28 | 242.70 | 46.0 | ||||||
| P/B | — | — | — | — | — | — | — | 6.08 | 1.80 | 0.00 | 2.16 | 2.6 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 15.75 | 89.73 | 128.10 | 35.2 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (1.19) | (0.67) | (2.15) | (3.25) | (1.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (35) | (61) | (78) | (86) | +49.9% | |||||
| Capex | — | — | — | — | — | — | — | (2) | (2) | (2) | (2) | (9.2%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (37) | (64) | (80) | (88) | +46.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 15 | 58 | (6) | 242 | n/m | |||||
| Net debt | — | — | — | — | — | — | — | (20) | (70) | (13) | (257) | (21.1%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | 19 | 63 | 0 | 252 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (137.18) | (181.58) | (66.31) | (181.6) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | (187.03) | (301.60) | (75.13) | (301.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 138 | 136 | 174 | — | +12.3% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.02 | 0.02 | 0.01 | — | (25.5%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Anteris Technologies Global Corp. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CTKB Cytek Biosciences, Inc. | $701.9M | — (loss-making) | — (loss-making) | +1.79% (above 0%: growing) | n/m | −30.25% (below 0%: shrinking) | 58.63% | (15.82%) | Compare |
| TCMD Tactile Systems Technology, Inc. | $590.7M | 25.2× | 20.6× | +7.12% (above 0%: growing) | −14.49% (below 0%: shrinking) | +23.84% (above 0%: growing) | 76.74% | 10.44% | Compare |
| AVR Anteris Technologies Global Corp. | $544.0M | — (loss-making) | — | +63.27% (above 0%: growing) | n/m | −6.84% (below 0%: shrinking) | 76.91% | (3,072.05%) | |
| SGHT Sight Sciences, Inc. | $537.7M | — (loss-making) | — (loss-making) | +25.20% (above 0%: growing) | n/m | +72.21% (above 0%: growing) | 85.94% | (24.59%) | Compare |
| DCTH Delcath Systems, Inc. | $502.8M | 1,455× | — (loss-making) | +20.60% (above 0%: growing) | −12.50% (below 0%: shrinking) | −24.45% (below 0%: shrinking) | 89.75% | 8.22% | Compare |
| NPCE NeuroPace, Inc. | $435.6M | — (loss-making) | — (loss-making) | −2.95% (below 0%: shrinking) | n/m | −78.70% (below 0%: shrinking) | 82.83% | (22.53%) | Compare |
| CERS Cerus Corporation | $430.2M | — (loss-making) | — (loss-making) | +6.28% (above 0%: growing) | n/m | +2,471.28% (above 0%: growing) | 57.12% | 0.60% | Compare |
| SENS Senseonics Holdings, Inc. | $422.5M | — (loss-making) | — (loss-making) | +117.82% (above 0%: growing) | n/m | −223.24% (below 0%: shrinking) | 59.10% | (248.48%) | Compare |
| MASS 908 Devices Inc. | $419.5M | — (loss-making) | — (loss-making) | +23.31% (above 0%: growing) | n/m | +150.95% (above 0%: growing) | 51.90% | (79.69%) | Compare |
| Median of peers | $469.2M | — | — | +13.86% | — | −0.30% | 67.92% | (19.17%) |
Pay and ownership Proxy statement filed 10 November 2025
Ownership
Directors and executive officers, together
4.50%
L1 Capital Pty Ltd
18.70%
Sio Capital Management, LLC
8.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement